JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Investing.com -- Telomir Pharmaceuticals Inc (NASDAQ:TELO) stock surged 150% following the release of preclinical data showing its lead drug candidate outperformed established cancer treatments in restoring tumor suppressor gene function.
The clinical-stage biotechnology company reported that its Telomir-1 compound demonstrated superior efficacy compared to Paclitaxel and Rapamycin in reversing epigenetic gene silencing in aggressive human prostate cancer cells. The drug fully reversed hypermethylation of STAT1, a master regulator of immune surveillance, in a dose-dependent manner during a 21-day oral administration in a mouse model.
According to the company, Telomir-1 may reactivate the body’s natural tumor suppressor system by restoring STAT1 activity, potentially allowing immune cells to recognize and eliminate cancer cells. This mechanism could explain the tumor shrinkage observed in previous studies.
"This study provides novel and direct molecular evidence of Telomir-1’s ability to reprogram cancer epigenetics," said Erez Aminov, CEO of Telomir. "By potentially restoring the function of key tumor suppressor genes like STAT1, we’re not just slowing tumor growth-we’re turning the immune system back on."
The company also reported that Telomir-1 reduced hypermethylation of TMS1, another tumor suppressor gene involved in programmed cell death and inflammasome activation. This dual action on both STAT1 and TMS1 distinguishes Telomir-1 from the comparison treatments in the study.
Telomir Pharmaceuticals is developing therapies targeting biological aging and age-related diseases. The company remains in the preclinical stage, with no products yet approved for commercial use.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.